Alpha Cognition Share Holder Equity 2020-2024 | ACOG
Alpha Cognition share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Alpha Cognition Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$-5 |
| 2022 |
$-1 |
| 2021 |
$9 |
| 2020 |
$0 |
| 2019 |
$5 |
Alpha Cognition Quarterly Share Holder Equity
(Millions of US $) |
| 2024-06-30 |
$-1 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$-5 |
| 2023-09-30 |
$-6 |
| 2023-06-30 |
$-0 |
| 2023-03-31 |
$1 |
| 2022-12-31 |
$-1 |
| 2022-09-30 |
$2 |
| 2022-06-30 |
$4 |
| 2022-03-31 |
$7 |
| 2021-12-31 |
$9 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$-1 |
| 2021-03-31 |
$-1 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$0 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
$5 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.035B |
$0.000B |
|
Alpha Cognition Inc. is a clinical stage biopharmaceutical company. It involved in developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. Alpha Cognition Inc. is based in Vancouver, British Columbia.
|
